Connect with us

Markets

How the World’s Most Elite Growth Investors Pick Stocks

Published

on

Investing can be extremely psychologically demanding.

Not only are you up against the world’s best investors, but you’re also up against yourself. It’s easy to get caught making irrational decisions based on your own personal blindspots or cognitive biases, and these mistakes can lead to buying when you should sell, and vice versa.

For the above reasons, the most successful investors are often those that have rational and proven systems in place.

Having a method to your madness allows you to have confidence in your decisions, while also taking advantage of the strategies and heuristics that have performed well for the world’s most elite investors.

How to Pick Growth Stocks

Today’s infographic comes to us from Investor’s Business Daily, and it details the basics around the discipline of growth investing, including the differences the school has with value investing.

More importantly, it also provides a framework for choosing growth stocks used by elite investors such as William J. O’Neil.

How the World's Most Elite Growth Investors Pick Stocks

Growth investing is all about identifying the companies that are exhibiting behavior that suggests that they will be tomorrow’s leaders.

The benefits to this strategy, if successful, are easy to see. Think about buying Microsoft before it dominated the software industry, or Starbucks before it conquered the United States with its new approach to coffee culture.

The question is: how can these stocks be found reliably?

The CAN SLIM Approach

Fantastic growth stocks don’t just grow on trees – instead, you have to have a system to sift through them.

One easy place to start your search for the next growth leader is with an approach pioneered with investing legend William J. O’Neil. Developed in the 1950s, the CAN SLIM strategy identifies seven characteristics that top-performing stocks often share before making their biggest price gains.

Each characteristic is represented by a letter in the CAN SLIM acronym:

C – Current quarterly earnings
A – Annual earnings growth
N – New product, service, management, or price high
S – Supply and demand
L – Leader or laggard
I – Institutional sponsorship
M – Market direction

Importantly, each of these traits can be a catalyst to influence other traits. When they compound, it can lead to big price movements that beat the rest of the market.

Breaking Down the Factors

Let’s look at each characteristic of the CAN SLIM approach in more detail:

Current quarterly earnings
Look for companies with a minimum earnings-per share (EPS) growth of 25% in the most recent quarter, though 50% or higher is even better. These companies should also have 20% sales growth in the quarter, and a 17% ROE to ensure that growth is sustainable.

Annual earnings growth
Look for companies with annual EPS growth of at least 25% to 50% in each of the previous 3-5 years. This helps confirm that the company is showing long-term growth.

New product, service, management, or price high
What is the company doing that is new or game-changing? To be a market winner, a company must constantly reinvent itself to position itself for higher-than-average profits.

Examples: Consider Google’s monetization of search ads, or McDonald’s novel approach to food. These innovations set the companies up for massive profits and success.

Supply and demand
A stock price increases when more investors demand an increasingly limited supply of shares. Spikes in price, along with volume accumulation, mean that demand is increasing. If this is coming from institutional investors, who tend to buy and hold, it’s even better.

Leader or laggard
The leading companies in leading industries – the best of the best – will be the companies that have the most growth potential.

Institutional sponsorship
75% of all market activity comes from professional investors, such as mutual funds or pension funds. Not only does the smart money help validate a potential growth stock by being involved, but they can trigger big price increases.

Market direction
CAN SLIM investors believe you should invest with the market, as opposed to against it. That’s because an individual stock moves with the market 75% of the time.

Putting it Together

Understanding how the different CAN SLIM factors work together – and how they can help bring massive bouts of growth for the underlying stock – is key for the successful growth investor.

Using a rational system like this also helps you in overcoming cognitive biases or making other mistakes that may affect your investments, as well.

Subscribe to Visual Capitalist

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Continue Reading
Comments

Energy

All the World’s Coal Power Plants in One Map

Today’s interactive map shows all of the world’s coal power plants, plotted by capacity and carbon emissions from 2000 until 2018.

Published

on

All The World’s Coal Power Plants in One Map

The use of coal for fuel dates back thousands of years.

Demand for the energy source really started to soar during the Industrial Revolution, and it continues to power some of the world’s largest economies today. However, as the clean energy revolution heats up, will coal continue to be a viable option?

Today’s data visualization from Carbon Brief maps the changing number of global coal power plants operating between 2000 and 2018. The interactive timeline pulls from the Global Coal Plant Tracker’s latest data and features around 10,000 retired, operating, and planned coal units, totaling close to 3,000 gigawatts (GW) of capacity across 95 countries.

On the map, each circular icon’s size represents each plant’s coal capacity in megawatts (MW). The data also highlights the type of coal burned and the CO₂ emissions produced as a result.

A Precarious Power Source

Throughout its history, coal has been used for everything from domestic heating and steel manufacturing, to railways, gas works, and electricity. The fuel played a pivotal role in powering economic development, and had a promising future with a flurry of plant openings.

However, in 2016, coal output dropped by 231 million tons of oil equivalent (Mtoe). Combined with a rapid slowdown of new plants being built, total coal units operating around the world fell for the first time in 2018.

With the remaining fleet of plants operating fewer hours than ever, plant closures have been triggered in South Africa, India, and China—steadily eroding coal’s bottom line. Industry trends have also forced a wave of coal companies to recently declare bankruptcy, including giants such as Peabody Energy and Alpha Natural.

Can Coal Compete with Clean Energy?

Today, coal is experiencing fierce competition from low-priced natural gas and ever-cheaper renewable power—most notably from wind and solar. Further, solar power costs will continue to decline each year and be cut in half by 2020, relative to 2015 figures.

chart

Source: Lazard

Natural gas surpassed coal as America’s #1 power source in 2016, with the total share of power generated from coal tumbling from 45% in 2010 to 28% in 2018. By next year, the role of coal is expected to be further reduced to 24% of the mix.

On the interactive visualization, the decline of coal is especially evident in 2018 as plant closures sweep across the map. The chart shows how several countries, notably China and India, have been closing many hundreds of smaller, older, and less efficient units, but replacing them with larger and more efficient models.

As of today, China retains the largest fleet of coal plants, consuming a staggering 45% of the world’s coal.


Use the above slider to see the difference between China’s coal plants in 2000 with projected future capacity.

Towards a New Reality

Coal is the most carbon intensive fossil fuel, and for every tonne of coal burned there are approximately 2.5 tonnes of carbon emissions. The International Energy Agency states that all unabated coal must be phased out within a few decades if global warming is to be limited.

Despite these warnings, global coal demand is set to remain stable for the next five years, with declines in the U.S. and Europe offset by immediate growth in India and China. The latter are the main players in the global coal market, but will eventually see a gradual decline in demand as they move away from industrialization.

A total phaseout of unabated coal is planned by 14 of the world’s 78 coal-powered countries, with many of these countries working to convert coal capacity to natural gas.

As the price of premium solar generation drops steadily, and innovation in renewable energy technology becomes more prominent, the world is shifting its attention to a clean energy economy. A global revival of coal looks less and less likely—and the fossil fuel might very well one day become obsolete.

Editor’s Note: The map uses WebGL and will not work on some older browsers. The map may also fail to load if you are using an ad-blocking browser plugin.

Subscribe to Visual Capitalist

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Continue Reading

Cannabis

The Big Pharma Takeover of Medical Cannabis

The Big Pharma industry is entering the cannabis space, by swapping patients for patents. But what are the impacts of such a takeover?

Published

on

The Big Pharma Takeover of Medical Cannabis

As evidence of cannabis’ many benefits mounts, so does the interest from the global pharmaceutical industry, known as Big Pharma. The entrance of such behemoths will radically transform the cannabis industry—once heavily stigmatized, it is now a potentially game-changing source of growth for countless companies.

Today’s infographic comes to us from CB2 Insights, and explores how and why the notorious Big Pharma are interested in the nascent cannabis industry.

Who are “Big Pharma”?

The term refers to some of the largest pharmaceutical companies in the world, considered especially influential as a group. To give a sense of their sheer size, the market cap of the top 10 Big Pharma companies is $1.7 trillion—Johnson & Johnson being the largest, with a market capitalization of $374 billion.

So far, Big Pharma has watched the cannabis industry from the sidelines, deterred by regulatory concerns. What we are seeing now is the sleeping giant’s takeover slowly intensifying as more patents, partnerships, and sponsored clinical trials come to fruition.

Could Cannabis be Sold Over the Counter?

The cannabis plant has been used in medicine for 6,000 years. However, there is still considerable debate around the role it plays in healthcare today. There are currently almost 400 active and completed clinical trials worldwide surrounding cannabidiol (CBD), a type of cannabinoid that makes up 40% of the cannabis plant’s extract.

Cannabis relies on CBD’s therapeutic properties, and recent studies suggest it may be useful in combating a variety of health conditions, such as:

  • Epilepsy
  • Schizophrenia
  • Multiple sclerosis
  • Migraines
  • Arthritis
  • Cancer side effects

As of 2019, 33 states and the District of Columbia have legalized cannabis for medical use. Its potential for pain management has led some experts to recommend it as an alternative to addictive painkillers, with one study of 13 states showing opiate-related deaths decreasing by over 33% in the six years since medical cannabis was legalized.

As the industry evolves, data is becoming increasingly important in understanding the potential of cannabis—both as a viable medical treatment, and as a recreational product. The shift away from anecdotal evidence towards big data will inform future policies, and give rise to a new era of consumer education.

Big Pharma’s Foray into Cannabis

Further legalization of cannabis will challenge Big Pharma’s bottom line, and poach more than $4 billion from pharma sales annually. In fact, medical cannabis sales are projected to reach $5.9 billion in 2019, from an estimated 24 million patients.

Seven of Canada’s top 10 cannabis patent holders are major multinational pharmaceutical companies, a trend that is not unique to Canada.

Company Rank🇨🇦 Canadian PatentsCompany Rank🇺🇸 U.S. Patents
1. Novartis211. Abbvie59
2. Pfizer142. Sanofie39
3. GW Pharmaceuticals133. Merck35
4. Ericsson134. Bristol-Myers Squibb34
5. Merck115. GW Pharmaceuticals28
6. Solvay Pharmaceuticals76. Pfizer25
7. Kao Corporation77. Hebrew University of Jerusalem19
8. Ogeda SA78. Roche17
9. Sanofi69. University of Connecticut16
10. University of Connecticut610. U.S. Health and Human Services13

It comes as no surprise that many pharmaceutical giants have already formed strong partnerships with cannabis companies, such as Novartis and Tilray, who will develop and distribute medical cannabis together in legal jurisdictions around the world.

Data is the Missing Link

While the body of knowledge about the many uses of cannabis continue to grow, clinical evidence is key for widespread adoption.

Products backed by data will be a defining criteria for major companies to come into the market en masse. And ultimately, Big Pharma’s entry could accelerate public understanding and confidence in cannabis as a viable option for a range of ailments, and mark the next major milestone for the industry.

Subscribe to Visual Capitalist

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Continue Reading
Standard Lithium Company Spotlight

Subscribe

Join the 120,000+ subscribers who receive our daily email

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Popular